Recombinant IL-2 given intra-splenically and intravenously in advanced malignant melanoma: a phase I/II study.
Affiliation
Christie Hospital & Paterson Institute of Cancer Research, Manchester, U.K.Issue Date
1989-06
Metadata
Show full item recordCitation
Recombinant IL-2 given intra-splenically and intravenously in advanced malignant melanoma: a phase I/II study. 1989, 16 Suppl A:49-52 Cancer Treat RevJournal
Cancer Treatment ReviewsPubMed ID
2788506Type
ArticleLanguage
enISSN
0305-7372Related articles
- Recombinant interleukin-2 (rIL-2) given intrasplenically and intravenously for advanced malignant melanoma. A phase I and II study.
- Authors: Thatcher N, Dazzi H, Johnson RJ, Russell S, Ghosh AK, Moore M, Chadwick G, Craig RD
- Issue date: 1989 Nov
- Phase II study of intravenous bolus recombinant interleukin-2 in advanced malignant melanoma: Southwest Oncology Group study.
- Authors: Whitehead RP, Kopecky KJ, Samson MK, Costanzi JJ, Natale RB, Feun LG, Hersh EM, Rinehart JJ
- Issue date: 1991 Sep 4
- Alternating recombinant human interleukin-2 and dacarbazine in advanced melanoma. A multicentric phase II study.
- Authors: Stoter G, Shiloni E, Gundersen S, Cleton FJ, Iacobelli S, Bijman JT, Palmer P, Franks CR, Rodenhuis S
- Issue date: 1989 Jun
- Recombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: a phase II study.
- Authors: Thatcher N, Dazzi H, Mellor M, Ghosh A, Carrington B, Johnson RJ, Loriaux EM, Craig RP
- Issue date: 1990 Apr
- Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study.
- Authors: Parkinson DR, Abrams JS, Wiernik PH, Rayner AA, Margolin KA, Van Echo DA, Sznol M, Dutcher JP, Aronson FR, Doroshow JH
- Issue date: 1990 Oct